Italia markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,3600-0,0400 (-1,67%)
Alla chiusura: 04:00PM EDT
2,3600 -0,01 (-0,21%)
Dopo ore: 04:06PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,4000
Aperto2,4400
Denaro2,3300 x 100
Lettera2,4000 x 100
Min-Max giorno2,3500 - 2,6600
Intervallo di 52 settimane1,3200 - 3,9700
Volume435.772
Media Volume901.338
Capitalizzazione601,651M
Beta (5 anni mensile)-0,56
Rapporto PE (ttm)N/D
EPS (ttm)-0,9300
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A6,33
  • GlobeNewswire

    Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical produ

  • GlobeNewswire

    Lyell Immunopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the following upcoming healthcare conferences: Morgan Stanley 21st Annual Global Healthcare Conference Monday, September 11, 4:55 p.m. ET H.C. Wainwright 25th Annual Global Investment Conferen

  • GlobeNewswire

    Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

    Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company